Biotech and Pharmaceuticals Medicine

More

  • The non-binding recommendation could clear the way for the cheaper medication from Celltrion, which would only be the second in a new class of quasi-generic biotech drugs to reach the U.S. market. After nine hours of discussion the FDA panel of outside experts voted 21-3 in favor of approval for all the diseases currently indicated on Remicade's label.

  • Rio Olympics: Zika scare sparks warnings Tuesday, 9 Feb 2016 | 3:53 AM ET
    Aedes aegypti mosquitos known to carry the Zika virus.

    Kenya could pull out of this year's Rio Olympics due to concerns over the Zika virus outbreak in Brazil, the head of Kenya's Olympics committee said.

  • Feb 7- The rapidly spreading Zika virus is discouraging many Americans from traveling to Latin America and the Caribbean, with 41 percent of those aware of the disease saying they are less likely to take such a trip, a Reuters/Ipsos poll shows. The U.S. Centers for Disease Control and Prevention has advised pregnant women to avoid travel to areas with an active...

  • EXCLUSIVE-ZIKA VIRUS HAS DISCOURAGED TRAVEL TO LATIN AMERICA, CARIBBEAN FOR 41 PERCENT OF AMERICANS WHO ARE AWARE OF DISEASE- REUTERS/IPSOS POLL.

  • Condom makers step up to help with Zika effort Friday, 5 Feb 2016 | 4:23 PM ET

    The virus, which is spreading quickly across the Americas, is usually transmitted by mosquitoes. But, the first known case contracted in the United States was a person infected after having sex with someone who had returned from Venezuela. World Health Organization spokesman Gregory Hartl stressed that "almost a 100 percent of the cases" are transmitted by the...

  • Feb 5- The U.S. Centers for Disease Control and Prevention on Friday revised its guidelines for pregnant women to include a recommendation that even those without symptoms of the Zika infection be tested after returning from affected areas. There is no vaccine or treatment for Zika, which has caused outbreaks in at least 26 countries in the Americas.

  • FRANKFURT, Feb 5- Europe's drug regulator said on Friday the defective blood clotting test device used in a key trial for the approval of Bayer's top-selling anti-clotting drug Xarelto did not distort the study's main findings. "Xarelto can continue to be used as before, in line with the current prescribing information," the European Medicines Agency said on its...

  • FDA scientists released their supportive findings ahead of a scheduled meeting on Tuesday of an independent medical advisory panel to the agency. "In considering the totality of the evidence, the data submitted by Celltrion show that is highly similar to U.S.-licensed Remicade" in treatment of rheumatoid arthritis and a related condition called...

  • FRANKFURT, Feb 5- Europe's drug regulator said on Friday the defective blood clotting test device used in a key trial for the approval of Bayer's top-selling anti-clotting drug Xarelto did not distort the main findings.

  • Feb 4- U.S. Food and Drug Administration staff members on Friday said clinical data from Celltrion Inc's biosimilar form of blockbuster arthritis drug Remicade indicated it is "highly similar" to the branded product in terms of safety, purity and potency. FDA scientists released their supportive findings ahead of a scheduled meeting on Tuesday of an...

  • NEW YORK, Feb 4- Rollins Inc, parent of extermination company Orkin, has seen its shares jump 5 percent during this year's stock market selloff because investors expect fears of the mosquito-borne Zika virus will lead to increased revenues. The virus, rapidly spreading in the Americas, has been linked to thousands of babies in Brazil being born with microcephaly,...

  • Johnson& Johnson, continuing its long quest for a Type 1 diabetes cure, is joining forces with biotech company ViaCyte to speed development of the first stem cell treatment that could fix the life-threatening hormonal disorder. They've already begun testing it in a small number of diabetic patients. ViaCyte and Johnson& Johnson's Janssen BetaLogics group...

  • Feb 3- Lloyd Blankfein, chief executive and chairman of Goldman Sachs Group Inc, said on Wednesday he was "feeling great" after his cancer treatment. The New Yorker is credited with helping to keep the company afloat during the financial crisis with an early decision to rein in exposure to risky mortgage-backed securities and a successful appeal to Warren...

  • Feb 3- Lloyd Blankfein, chief executive and chairman of Goldman Sachs Group Inc, told CNBC on Wednesday that he is "feeling great" after the treatment for lymphoma. In his first interview after revealing in September that he had a "highly curable" form of cancer, Blankfein said he had undergone 600 hours of chemotherapy. The Wall Street bank's chairman also discussed...

  • LONDON, Feb 3- The world is once again asking scientists and drugmakers to come up rapidly with a vaccine for a viral disease that, in the latest case, few people had heard of until a few weeks ago, and even fewer feared. Making a shot to generate an immune response against Zika virus, which is sweeping through the Americas, shouldn't be too hard in theory.

  • Seven $1 billion-plus drugs seen reaching market in 2016 Wednesday, 3 Feb 2016 | 12:00 AM ET

    LONDON, Feb 3- Drug companies are likely to launch seven "blockbuster" drugs in 2016, each with $1 billion- plus annual sales potential, led by new treatments for liver disease and HIV, according to a Thomson Reuters analysis. The two top hits of 2016 are tipped to be Intercept Pharmaceuticals' chronic liver disease drug obeticholic acid, with a consensus sales...

  • LOS ANGELES, Feb 2- Gilead Sciences Inc's hepatitis C drug sales edged past Wall Street estimates in the fourth quarter, helped by strong sales in Japan, but U.S. results were weaker than expected. The company, which faces growing competition in the lucrative hepatitis C market, projected total 2016 product sales of $30 billion to $31 billion, in line with the...

  • LOS ANGELES, Feb 2- Gilead Sciences Inc's hepatitis C drug sales edged past Wall Street estimates in the fourth quarter, helped by strong sales in Japan, but U.S. results were weaker than expected. "It was a strong overall quarter, driven by strong Japan sales, but U.S. sales were lighter than expected," said Michael Yee at RBC Capital Markets. For full-year 2016, Gilead...

  • Feb 2- Gilead Sciences Inc's sales of hepatitis C drugs beat Wall Street estimates in the fourth quarter, helping to push the biotechnology company's shares 2 percent higher on Tuesday. For full-year 2016, Gilead projected total product sales of $30 billion to $31 billion, in line with the average Wall Street estimate of $30.68 billion as compiled by ISI...

  • Gilead beats on earnings, revenue Tuesday, 2 Feb 2016 | 4:00 PM ET
    A scientist at Gilead Sciences analyzes patient antibody levels at the Gilead laboratory in Foster City, California.

    Gilead reported quarterly earnings and revenue on Tuesday that beat analysts' expectations, boosted by sales of its drugs in Japan.